EAST PROVIDENCE – IlluminOss Medical Inc. said Monday that it has completed enrollment in its first U.S. clinical trial toward U.S. Food and Drug Administration approval of its IlluminOss System, a minimally invasive system to repair bone fractures. The clinical outcomes data collected will allow IlluminOss to submit a DeNovo marketing application to the FDA…
Want More Free?
To access 2 more articles, please log in or register for free.
Registered users get access to a limited number of free articles every month.